Table 1.
Baseline Characteristics | Overall Study Cohort, n=126 | Number of APOL1 High-Risk Alleles | |
---|---|---|---|
0 or 1, n=110; 87% | 2, n=16; 13% | ||
Age, median (25th–75th) | 60 (47–73) | 58 (47–73) | 62 (59–78) |
Body mass index, median (25th–75th) | 32.9 (26.0–39.1) | 32.6 (25.8–39.4) | 34.1 (27.7–38.1) |
Men, n (%) | 52 (41) | 45 (41) | 7 (44) |
Hypertension, n (%) | 83 (66) | 70 (64) | 13 (81) |
eGFR, median (25th–75th%) | 85 (63–103) | 90 (66–106) | 68 (50–89) |
Use of ACEi/ARB, n (%) | 34 (27) | 31 (28) | 3 (19) |
Inpatient status, n (%) | 65 (52) | 54 (49) | 11 (69) |
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.